ALEC
Alector, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.91
+3.24%Sep 17, 2026, 13:30 UTC
Novartis halted development of its investigational ALS therapy VHB937 after the ASTRALS Phase 2 trial failed to meet its primary or secondary endpoints.
Source:Aug 7, 2026, 00:12 UTC
Alector reported a second-quarter loss of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.24 and improving from a loss of $0.30 per share a year earlier.
Source:Jul 8, 2026, 21:20 UTC
GSK terminated its neuroscience collaboration agreement with Alector covering two experimental antibody drugs after both drug candidates suffered clinical setbacks.
Source: